+

WO2003064619A3 - Compositions a action prolongee d'hormones et de facteurs de croissance et leurs utilisations - Google Patents

Compositions a action prolongee d'hormones et de facteurs de croissance et leurs utilisations Download PDF

Info

Publication number
WO2003064619A3
WO2003064619A3 PCT/US2003/002982 US0302982W WO03064619A3 WO 2003064619 A3 WO2003064619 A3 WO 2003064619A3 US 0302982 W US0302982 W US 0302982W WO 03064619 A3 WO03064619 A3 WO 03064619A3
Authority
WO
WIPO (PCT)
Prior art keywords
long
growth factor
fsh
vegf
factor compositions
Prior art date
Application number
PCT/US2003/002982
Other languages
English (en)
Other versions
WO2003064619A2 (fr
Inventor
Joyce Lustbader
Leslie Lobel
Original Assignee
Univ Columbia
Joyce Lustbader
Leslie Lobel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia, Joyce Lustbader, Leslie Lobel filed Critical Univ Columbia
Priority to AU2003216144A priority Critical patent/AU2003216144A1/en
Publication of WO2003064619A2 publication Critical patent/WO2003064619A2/fr
Publication of WO2003064619A3 publication Critical patent/WO2003064619A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des composés de VEGF-FSH possédant des demi-vies sériques augmentées par rapport à VEGF ou FSH natifs, dans lesquels à la fois VEGF et FSH sont biologiquement actifs. Elle concerne également des compositions et des procédés apparentés servant à augmenter la fertilité, la production d'ovules et la spermatogénèse chez un individu, ainsi que des procédés servant à augmenter la vascularisation d'un tissu, en particulier, le tissu ovarien.
PCT/US2003/002982 2002-01-31 2003-01-31 Compositions a action prolongee d'hormones et de facteurs de croissance et leurs utilisations WO2003064619A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003216144A AU2003216144A1 (en) 2002-01-31 2003-01-31 Long-acting hormone and growth factor compositions and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6293102A 2002-01-31 2002-01-31
US10/062,931 2002-01-31
US10/119,427 US7173113B2 (en) 2002-01-31 2002-04-09 Long-acting hormone and growth factor compositions and uses thereof
US10/119,427 2002-04-09

Publications (2)

Publication Number Publication Date
WO2003064619A2 WO2003064619A2 (fr) 2003-08-07
WO2003064619A3 true WO2003064619A3 (fr) 2004-04-01

Family

ID=27667768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/002982 WO2003064619A2 (fr) 2002-01-31 2003-01-31 Compositions a action prolongee d'hormones et de facteurs de croissance et leurs utilisations

Country Status (3)

Country Link
US (3) US7173113B2 (fr)
AU (1) AU2003216144A1 (fr)
WO (1) WO2003064619A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7173113B2 (en) * 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
US7081446B2 (en) * 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
KR100533794B1 (ko) * 2003-10-02 2005-12-07 주식회사 프로젠 인간 난포자극 호르몬을 대량으로 생산하는 방법
US20060026719A1 (en) * 2004-01-14 2006-02-02 Kieliszewski Marcia J Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US7553940B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048848B2 (en) * 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
CA2707352C (fr) * 2007-11-30 2020-10-27 Aspenbio Pharma, Inc. Activite d'hormone folliculo-stimulante equine recombinante
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2013152351A2 (fr) * 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Polypeptides de fusion et procédés pour les utiliser
KR20150008137A (ko) 2012-04-19 2015-01-21 옵코 바이오로직스 리미티드 지속성 옥신토모둘린 변이체 및 이의 생산 방법
EP2922867B1 (fr) 2012-11-20 2021-07-21 OPKO Biologics Ltd. Procédé d'augmentation du volume hydrodynamique de polypeptides par la fixation à des peptides carboxy terminaux de gonadotrophine
EP2968391A1 (fr) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Molécules polynucléotidiques à longue durée de vie
RU2526571C1 (ru) * 2013-04-08 2014-08-27 Сергей Михайлович Юдин Инъекционный препарат для повышения спермопродукции человека и способ его применения
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
ES2893616T3 (es) 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
SG11201900279UA (en) 2016-07-11 2019-02-27 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
WO2021078834A1 (fr) * 2019-10-22 2021-04-29 Genethon Polypeptides d'alpha-glucosidase acide chimériques et leurs utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712122A (en) * 1989-02-21 1998-01-27 Washington University Carboxy terminal peptide-extended proteins
US5958737A (en) * 1994-08-12 1999-09-28 Washington University Single-chain β subunit dimers of the glycoprotein hormones and recombinant materials related thereto

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5985611A (en) 1992-04-30 1999-11-16 Washington University Recombinant production of gonadotropins in secretory cells
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7173113B2 (en) 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712122A (en) * 1989-02-21 1998-01-27 Washington University Carboxy terminal peptide-extended proteins
US5958737A (en) * 1994-08-12 1999-09-28 Washington University Single-chain β subunit dimers of the glycoprotein hormones and recombinant materials related thereto

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEN-MENAHEM ET AL.: "The position of the alpha and beta subunits in a single chain variant of human chorionic gonadotropin affects the heterodimeric interaction of the subunits and receptor-binding epitopes", J. BIOL. CHEM., vol. 276, no. 32, August 2001 (2001-08-01), pages 29871 - 29879, XP002970104 *
BOULOUX ET AL.: "First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males", HUMAN REPRODUCTION, vol. 16, no. 8, August 2001 (2001-08-01), pages 1592 - 1597, XP001080293 *
FARES ET AL.: "Design of a long-acting follitropin agonist by fusing the -terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit", PROC. NATL. ACAD. SCI. USA, vol. 89, May 1992 (1992-05-01), pages 4304 - 4308, XP002057262 *

Also Published As

Publication number Publication date
US7173113B2 (en) 2007-02-06
US7442684B2 (en) 2008-10-28
US20090093411A1 (en) 2009-04-09
US20030144189A1 (en) 2003-07-31
WO2003064619A2 (fr) 2003-08-07
AU2003216144A1 (en) 2003-09-02
US20030216313A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
WO2003064619A3 (fr) Compositions a action prolongee d'hormones et de facteurs de croissance et leurs utilisations
WO2003064677A3 (fr) Analogues de l'hormone folliculostimulante a action prolongee et leurs utilisations
WO2007056362A3 (fr) Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
WO2005118620A3 (fr) Procedes de preparation de peptides et de peptidomimetiques a contrainte interne
EP2441838A3 (fr) Protéines de fusion contenant des jonctions naturelles
WO2007002261A3 (fr) Anticorps bloquant il-1$g(b) et leurs fragments
WO2005000222A3 (fr) Nouveaux procedes et nouvelles compositions pour une administration amelioree par voie muqueuse de peptides et de proteines
WO2005055983A3 (fr) Procede de preparation de cocristaux a phase mixte avec des agents actifs
AU2433901A (en) Chimeric natriuretic peptides
WO2002024909A3 (fr) Acides nucleiques et polypeptides de nouveau recepteur
TW200621789A (en) Fused thiophenes, methods for making fused thiophens, and uses thereof
DE60110054D1 (en) Cardioprotektive phosphonate
HK1117746A1 (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
WO2003082857A3 (fr) Polymorphes de lansoprazole et procedes de preparation de ces derniers
WO2004048517A3 (fr) Procede pour reduire ou prevenir la modification d'un peptide dans une solution
WO2006015120A3 (fr) Composition injectable stable de succinate alpha tocopherile, d'analogue et de sels de ce compose
WO2001047956A3 (fr) Procede permettant d'obtenir des proteines possedant de meilleures caracteristiques fonctionnelles
WO2005000359A3 (fr) Conjugues d'hormone de croissance humaine chimiquement modifies
WO2005000888A3 (fr) Nouveaux promoteurs de l'actine beta et de la rps21, et leurs utilisations
WO2004007664A3 (fr) Vecteurs d'acides nucleiques
AU2003260045A1 (en) Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
WO2006129120A3 (fr) Derives de benzotriazepinone
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
EP1189909A4 (fr) Nouveaux composes d'aluminosiloxane, et leur procede de preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载